Clinical Expert Commentaries

Clinical Expert Commentaries published on June 11, 2015
Stuart L. Goldberg, MD provides CML meeting highlights live from the 2015 ASCO Annual Meeting that significantly impact practice.

For additional meeting highlights from other congresses, click here
Clinical Expert Commentaries published on June 11, 2015
Jorge Eduardo Cortes, MD provides CML meeting highlights live from the 2015 ASCO Annual Meeting that significantly impact practice.

For additional meeting highlights from other congresses, click here
Clinical Expert Commentaries published on June 13, 2014
Dr. Stuart Goldberg discusses the 5-year data on the ENESTnd trial live from the 2014 ASCO Annual Meeting.
Clinical Expert Commentaries published on June 13, 2014
Dr. Stuart Goldberg discusses how to monitor newly diagnosed patients with chronic-phase chronic myeloid leukemia.
Clinical Expert Commentaries published on June 13, 2014
Dr. Stuart Goldberg discusses EPIC: A phase III trial of ponatinib versus imatinib in patients with newly diagnosed CP-CML live from the 2014 ASCO Annual Meeting.
Clinical Expert Commentaries published on January 15, 2014
Professor Giuseppe Saglio discusses recent updates to ELN and NCCN Guidelines, recommendations for monitoring response to therapy and the 4-year Update to the ENESTnd Trial.
Clinical Expert Commentaries published on November 29, 2013
Dr. Stuart Goldberg provides a brief history of chronic myeloid leukemia from the 1850s through the present day.
Clinical Expert Commentaries published on November 20, 2013
Dr. Stuart Goldberg provides an update on the recent events surrounding ponatinib and what community physicians should do while this agreed hold on sales of ponatinib remains in effect.
Clinical Expert Commentaries published on November 1, 2013
Dr. Stuart Goldberg discusses the definition of accelerated phase CML and strategies for managing your patients in accelerated phase and/or blast crisis in CML.
Clinical Expert Commentaries published on October 1, 2013
Dr. Jerald Radich discusses how to manage primary resistance and secondary treatments in CML.
Page 1 of 2
Results 1 - 10 of 12